专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008058287A1 COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER 审中-公开
标题翻译： ERA +配体和HISTONE脱乙酰酶抑制剂治疗癌症的联合
公开(公告)号：WO2008058287A1
公开(公告)日：2008-05-15
申请号：PCT/US2007/084355
申请日：2007-11-09
申请人： SYNDAX PHARMACEUTICALS, INC. , ORDENTLICH, Peter , HOROBIN, Joanna , WHITEHOUSE, Martha, Jo , REES, Miranda
发明人： ORDENTLICH, Peter , HOROBIN, Joanna , WHITEHOUSE, Martha, Jo , REES, Miranda
IPC分类号： A61K31/165 , A61K31/44 , A61K31/335 , A61P35/00
CPC分类号： A61K31/165 , A61K31/335 , A61K31/44 , A61K45/06 , A61K2300/00
摘要： The present embodiments relate to compositions and methods of treatment of cancer. More particularly, the present embodiments relate to the combination of an ERα+ ligand with an HDACi for the treatment of cancer, methods of treating cancer and pharmaceutical compositions for treating cancer.
摘要翻译：本实施方案涉及治疗癌症的组合物和方法。更具体地，本实施方案涉及ERa +配体与用于治疗癌症的HDACi的组合，治疗癌症的方法和用于治疗癌症的药物组合物。

2. 发明申请

WO2009140659A3 TREATING DYSPNEA ASSOCIATED WITH ACUTE HEART FAILURE WITH RELAXIN 审中-公开
公开(公告)号：WO2009140659A3
公开(公告)日：2009-11-19
申请号：PCT/US2009/044249
申请日：2009-05-15
申请人： CORTHERA, INC. , UNEMORI, Elaine , TEICHMAN, Sam, L. , COTTER, Gad , STEWART, Dennis, R. , WHITEHOUSE, Martha, Jo
发明人： UNEMORI, Elaine , TEICHMAN, Sam, L. , COTTER, Gad , STEWART, Dennis, R. , WHITEHOUSE, Martha, Jo
IPC分类号： A61K38/22 , C07K14/64 , A61P9/04
摘要： The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.

3. 发明申请

WO2009140657A3 METHOD OF TREATING CHRONIC HEART FAILURE 审中-公开
公开(公告)号：WO2009140657A3
公开(公告)日：2009-11-19
申请号：PCT/US2009/044247
申请日：2009-05-15
申请人： CORTHERA, INC. , UNEMORI, Elaine , TEICHMAN, Sam, L. , DSCHIETZIG, Thomas , STEWART, Dennis, R. , WHITEHOUSE, Martha, Jo
发明人： UNEMORI, Elaine , TEICHMAN, Sam, L. , DSCHIETZIG, Thomas , STEWART, Dennis, R. , WHITEHOUSE, Martha, Jo
IPC分类号： A61K38/00
摘要： The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin.

4. 发明申请

WO2002058720A2 ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF-2 AND METHOD OF USE 审中-公开
标题翻译： FGF-2的有效单位剂量及其使用方法
公开(公告)号：WO2002058720A2
公开(公告)日：2002-08-01
申请号：PCT/US2002/002239
申请日：2002-01-25
申请人： CHIRON CORPORATION , WHITEHOUSE, Martha, Jo
发明人： WHITEHOUSE, Martha, Jo
IPC分类号： A61K38/00
CPC分类号： A61K31/727 , A61K38/1825 , A61K2300/00
摘要： The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 OF SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts 2 months before retreatment is required. In another aspect, the present invention is directed to a method of administration which optimises patient's safety. In this embodiment, fluids, heparin and /or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.
摘要翻译：本发明具有多个方面。特别地，一方面，本发明涉及包含0.2μg/ kg至48μg/ kg的SEQ ID NO：2的FGF-2或其血管生成活性片段或突变蛋白的单位剂量组合物药学上可接受的载体。另一方面，本发明涉及一种治疗冠状动脉疾病的人类患者的方法，其包括对需要治疗冠状动脉疾病的人类患者的一个或多个冠状动脉血管或外周静脉施用安全和血管生成有效剂量的重组FGF-2或其血管生成活性片段或突变蛋白。本发明的单一单位剂量组合物在需要再治疗2个月的人CAD患者中提供血管生成作用。另一方面，本发明涉及优化患者安全性的给药方法。在该实施方案中，流体，肝素和/或输注速率都起作用。在另一方面，本发明涉及药物组合物，其在治疗有效的载体中包含治疗有效量的单独或与肝素组合的FGF-2。效益的幅度和持续时间是意想不到的; 另外有利于IV路线是意想不到的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式